156 related articles for article (PubMed ID: 38034620)
1. Inflammatory predictors (eosinophil, C-RP and IL-6) and effectiveness of oral Azvudine tablets treatment in COVID-19 hospitalized patients: A retrospective, self-controlled study.
Zhao Y; Gao G; Li W; Xu Z; Wang X; Chang R
Heliyon; 2023 Nov; 9(11):e21941. PubMed ID: 38034620
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of azvudine against severe outcomes among hospitalized COVID-19 patients in Xinjiang, China: a single-center, retrospective, matched cohort study.
Kapar A; Xie S; Guo Z; Nan Y; Du Y; Yin X; Gong T; Gu X; Zhou Y; Lu W; Yang A; Luo Z; Dai J; Wang K; Zhao S; Wang K
Expert Rev Anti Infect Ther; 2024 May; ():. PubMed ID: 38822541
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
4. Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching.
Wei AH; Zeng L; Wang L; Gui L; Zhang WT; Gong XP; Li J; Liu D
Front Pharmacol; 2023; 14():1274294. PubMed ID: 37900159
[No Abstract] [Full Text] [Related]
5. Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine.
Mao M; Dian Y; Sun Y; Chen W; Zhu W; Deng G
Front Cell Infect Microbiol; 2023; 13():1237277. PubMed ID: 37920449
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Analysis of Azvudine in Patients with COVID-19 and Pre-existing Cancer.
Li F; Zheng K; Qi X; Cui K; Yang J; Hao Z
J Cancer; 2024; 15(8):2442-2447. PubMed ID: 38495484
[No Abstract] [Full Text] [Related]
7. Association of eosinopenia with worsening prognosis in hospitalized Azvudine-treated COVID-19 patients: a retrospective cohort study.
Wang X; Dian Y; Zhou Q; Deng G; Wei R; Zeng F
Front Immunol; 2023; 14():1320973. PubMed ID: 38162638
[TBL] [Abstract][Full Text] [Related]
8. Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients.
Su P; Yang CX; Wang XG
BMC Infect Dis; 2024 Jan; 24(1):44. PubMed ID: 38172735
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
Deng G; Li D; Sun Y; Jin L; Zhou Q; Xiao C; Wu Q; Sun H; Dian Y; Zeng F; Pan P; Shen M
J Med Virol; 2023 Apr; 95(4):e28756. PubMed ID: 37185838
[TBL] [Abstract][Full Text] [Related]
10. Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: Results of a real-world study.
Yang H; Wang Z; Jiang C; Zhang Y; Zhang Y; Xu M; Zhang Y; Wang Y; Liu X; An Z; Tong Z
J Med Virol; 2023 Jul; 95(7):e28947. PubMed ID: 37470209
[TBL] [Abstract][Full Text] [Related]
11. Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
Zhao Q; Zheng B; Han B; Feng P; Xia Z; Jiang H; Ying Y; Zhu J; Fei C; Xiang J; Shen L; Luo Q; Wu Y; Wusiman A; Xin C; Zhang M; Li G; Li X
Infect Dis Ther; 2023 Aug; 12(8):2087-2102. PubMed ID: 37486556
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study.
Ren Z; Luo H; Yu Z; Song J; Liang L; Wang L; Wang H; Cui G; Liu Y; Wang J; Li Q; Zeng Z; Yang S; Pei G; Zhu Y; Song W; Yu W; Song C; Dong L; Hu C; Du J; Chang J
Adv Sci (Weinh); 2020 Oct; 7(19):e2001435. PubMed ID: 35403380
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study.
Zhao X; Cheng Y; Zhang M; Qianda B; Zhouma B; Yangzhen B; Zheng Y; Zhang S; Zhao H
Infect Drug Resist; 2023; 16():6053-6060. PubMed ID: 37719651
[TBL] [Abstract][Full Text] [Related]
14. Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.
Sun Y; Jin L; Dian Y; Shen M; Zeng F; Chen X; Deng G
EClinicalMedicine; 2023 May; 59():101981. PubMed ID: 37193346
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials.
Zhu KW
Front Pharmacol; 2023; 14():1228548. PubMed ID: 37693894
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit.
Qi X; Yang Y; Gong B; Li Z; Liang D
J Thorac Dis; 2023 Sep; 15(9):4925-4937. PubMed ID: 37868850
[TBL] [Abstract][Full Text] [Related]
17. Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients.
de Souza SB; Cabral PGA; da Silva RM; Arruda RF; Cabral SPF; de Assis ALEM; Viana Junior AB; Degrave WMS; Moreira ADS; Silva CG; Chang J; Lei P
Front Med (Lausanne); 2023; 10():1215916. PubMed ID: 37928473
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory response of cardamom extract and prediction of therapeutic window in COVID-19 patients by assessing inflammatory markers using RT-PCR.
Shakeeb N; Varkey P; Hynse A; Mandlecha A
Inflammopharmacology; 2022 Jun; 30(3):883-894. PubMed ID: 35320494
[TBL] [Abstract][Full Text] [Related]
19. Azvudine and mortality in patients with coronavirus disease 2019: A retrospective cohort study.
Liu B; Yang M; Xu L; Li Y; Cai J; Xie B; Zong K; Guo S
Int Immunopharmacol; 2023 Nov; 124(Pt A):110824. PubMed ID: 37633242
[TBL] [Abstract][Full Text] [Related]
20. Azvudine therapy of common COVID-19 in hemodialysis patients.
Shang S; Fu B; Geng Y; Zhang J; Zhang D; Xiao F; Sheng Z; Zhai J; Li W; Chen X; Zheng C; Li Q
J Med Virol; 2023 Aug; 95(8):e29007. PubMed ID: 37522276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
